These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 10470206

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy.
    Shen S, Lepor H, Yaffee R, Taneja SS.
    J Urol; 2005 Mar; 173(3):777-80. PubMed ID: 15711268
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The periurethral glands do not significantly influence the serum prostate specific antigen concentration.
    Oesterling JE, Tekchandani AH, Martin SK, Bergstralh EJ, Reichstein E, Diamandis EP, Yemoto C, Stamey TA.
    J Urol; 1996 May; 155(5):1658-60. PubMed ID: 8627847
    [Abstract] [Full Text] [Related]

  • 5. Usefulness of ultrasensitive prostate-specific antigen assay for early detection of biochemical failure after radical prostatectomy.
    Nakamura M, Hasumi H, Miyoshi Y, Sugiura S, Fujinami K, Yao M, Kubota Y, Uemura H.
    Int J Urol; 2005 Dec; 12(12):1050-4. PubMed ID: 16409609
    [Abstract] [Full Text] [Related]

  • 6. Supersensitive PSA-analysis after radical prostatectomy: a powerful tool to reduce the time gap between surgery and evidence of biochemical failure.
    Haese A, Huland E, Graefen M, Huland H.
    Anticancer Res; 1999 Dec; 19(4A):2641-4. PubMed ID: 10470210
    [Abstract] [Full Text] [Related]

  • 7. The analytical and clinical performance of the new Boehringer Mannheim Enzymun-Test PSA assay for prostate-specific antigen.
    Blijenberg BG, Eman I, Boevé ER, Mössner E, Uhl W.
    Eur J Clin Chem Clin Biochem; 1995 Jun; 33(6):383-92. PubMed ID: 7578619
    [Abstract] [Full Text] [Related]

  • 8. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
    Stamey TA, Johnstone IM, McNeal JE, Lu AY, Yemoto CM.
    J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
    [Abstract] [Full Text] [Related]

  • 9. Detection rates and biologic significance of prostate cancer with PSA less than 4.0 ng/mL: observation and clinical implications from Tyrol screening project.
    Pelzer AE, Tewari A, Bektic J, Berger AP, Frauscher F, Bartsch G, Horninger W.
    Urology; 2005 Nov; 66(5):1029-33. PubMed ID: 16286118
    [Abstract] [Full Text] [Related]

  • 10. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer.
    Brawer MK, Cheli CD, Neaman IE, Goldblatt J, Smith C, Schwartz MK, Bruzek DJ, Morris DL, Sokoll LJ, Chan DW, Yeung KK, Partin AW, Allard WJ.
    J Urol; 2000 May; 163(5):1476-80. PubMed ID: 10751861
    [Abstract] [Full Text] [Related]

  • 11. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
    Becker C, Piironen T, Pettersson K, Björk T, Wojno KJ, Oesterling JE, Lilja H.
    J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
    [Abstract] [Full Text] [Related]

  • 12. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride.
    Andriole GL, Marberger M, Roehrborn CG.
    J Urol; 2006 May; 175(5):1657-62. PubMed ID: 16600723
    [Abstract] [Full Text] [Related]

  • 13. Biochemical relapse of prostate cancer. Evidence after radical surgery.
    Prott FJ, Spitz J, Michaelis M, Niles B, Barth S, Köllermann M, Kleinschmidt K.
    Anticancer Res; 2003 May; 23(2A):979-81. PubMed ID: 12820334
    [Abstract] [Full Text] [Related]

  • 14. Inadequacy of prostate-specific antigen doubling time estimates calculated using an ultrasensitive assay of prostate-specific antigen for biochemical failure after radical prostatectomy.
    Shimizu F, Matsuyama Y, Tominaga T, Ohashi Y, Fujime M.
    Urol Int; 2007 May; 79(4):356-60. PubMed ID: 18025856
    [Abstract] [Full Text] [Related]

  • 15. Super-sensitive prostate-specific antigen (PSA) in serum of women with benign breast disease or breast cancer.
    Hautmann S, Huland E, Grupp C, Haese A, Huland H.
    Anticancer Res; 2000 May; 20(3B):2151-4. PubMed ID: 10928169
    [Abstract] [Full Text] [Related]

  • 16. The relationship of ultrasensitive measurements of prostate-specific antigen levels to prostate cancer recurrence after radical prostatectomy.
    Taylor JA, Koff SG, Dauser DA, McLeod DG.
    BJU Int; 2006 Sep; 98(3):540-3. PubMed ID: 16925750
    [Abstract] [Full Text] [Related]

  • 17. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial.
    Southwick PC, Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, Walsh PC, Scardino PT, Lange PH, Gasior GH, Parson RE, Loveland KG.
    J Urol; 1999 Oct; 162(4):1346-51. PubMed ID: 10492194
    [Abstract] [Full Text] [Related]

  • 18. Undetectable ultrasensitive PSA after radical prostatectomy for prostate cancer predicts relapse-free survival.
    Doherty AP, Bower M, Smith GL, Miano R, Mannion EM, Mitchell H, Christmas TJ.
    Br J Cancer; 2000 Dec; 83(11):1432-6. PubMed ID: 11076649
    [Abstract] [Full Text] [Related]

  • 19. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
    Mäkinen T, Tammela TL, Hakama M, Stenman UH, Rannikko S, Aro J, Juusela H, Määttänen L, Auvinen A.
    J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
    [Abstract] [Full Text] [Related]

  • 20. Efficiency of ultrasensitive prostate-specific antigen assay in diagnosing biochemical failure after radical prostatectomy.
    Shimizu F, Tanaka S, Matsuyama Y, Tominaga T, Ohashi Y, Fujime M.
    Jpn J Clin Oncol; 2007 Jun; 37(6):446-51. PubMed ID: 17656483
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.